NZ590891A - Neutralizing anti-influenza a virus antibodies and uses thereof - Google Patents

Neutralizing anti-influenza a virus antibodies and uses thereof

Info

Publication number
NZ590891A
NZ590891A NZ590891A NZ59089109A NZ590891A NZ 590891 A NZ590891 A NZ 590891A NZ 590891 A NZ590891 A NZ 590891A NZ 59089109 A NZ59089109 A NZ 59089109A NZ 590891 A NZ590891 A NZ 590891A
Authority
NZ
New Zealand
Prior art keywords
influenza
neutralizing anti
virus antibodies
subtypes
antibody
Prior art date
Application number
NZ590891A
Other languages
English (en)
Inventor
Antonio Lanzavecchia
Original Assignee
Inst Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Research In Biomedicine filed Critical Inst Research In Biomedicine
Publication of NZ590891A publication Critical patent/NZ590891A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ590891A 2008-07-25 2009-07-27 Neutralizing anti-influenza a virus antibodies and uses thereof NZ590891A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8383808P 2008-07-25 2008-07-25
US18158209P 2009-05-27 2009-05-27
PCT/IB2009/006623 WO2010010467A2 (en) 2008-07-25 2009-07-27 Neutralizing anti-influenza a virus antibodies and uses thereof

Publications (1)

Publication Number Publication Date
NZ590891A true NZ590891A (en) 2013-03-28

Family

ID=41570664

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ590891A NZ590891A (en) 2008-07-25 2009-07-27 Neutralizing anti-influenza a virus antibodies and uses thereof
NZ590890A NZ590890A (en) 2008-07-25 2009-07-27 Neutralizing anti-influenza a virus antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ590890A NZ590890A (en) 2008-07-25 2009-07-27 Neutralizing anti-influenza a virus antibodies and uses thereof

Country Status (20)

Country Link
US (2) US9340603B2 (enExample)
EP (2) EP2313433A2 (enExample)
JP (3) JP2011528902A (enExample)
KR (2) KR20110049802A (enExample)
CN (2) CN102216327A (enExample)
AU (2) AU2009275227A1 (enExample)
BR (1) BRPI0911699B8 (enExample)
CA (2) CA2733218A1 (enExample)
CO (1) CO6341572A2 (enExample)
CR (2) CR20110079A (enExample)
EC (1) ECSP11010823A (enExample)
ES (1) ES2662519T3 (enExample)
GT (1) GT201100023A (enExample)
IL (2) IL210772A0 (enExample)
MA (1) MA32577B1 (enExample)
MX (2) MX2011000768A (enExample)
NZ (2) NZ590891A (enExample)
RU (1) RU2553325C2 (enExample)
WO (2) WO2010010466A2 (enExample)
ZA (2) ZA201101113B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708221C (en) 2007-12-06 2017-07-25 Wayne A. Marasco Antibodies against influenza virus and methods of use thereof
AU2009275227A1 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP2545074A4 (en) * 2010-03-08 2014-01-08 Celltrion Inc HUMAN MONOCLONAL ANTIBODIES MADE FROM HUMAN B-CELLS WITH NEUTRALIZING EFFECT AGAINST INFLUENZA A-VIRUS
CA2839421C (en) * 2010-06-17 2019-12-03 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
EP2699688A1 (en) 2011-04-20 2014-02-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
US8961978B2 (en) * 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
LT3418300T (lt) * 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas
CN107417789A (zh) * 2011-07-18 2017-12-01 生物医学学会 中和抗甲型流感病毒抗体及其用途
AU2012289926A1 (en) * 2011-08-03 2014-03-13 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
US9512202B2 (en) 2011-08-27 2016-12-06 University Of Zurich Multi-strain-reactive antibodies for therapy and diagnosis of influenza
JP5998222B2 (ja) * 2011-09-30 2016-09-28 セルトリオン・インコーポレイテッド ヒトｂ細胞で生産されたインフルエンザａウイルス中和活性を持つ結合分子
CA2852474A1 (en) * 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
KR20130059721A (ko) * 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
SG11201402780UA (en) 2011-12-02 2014-10-30 Aimm Therapeutics Bv Influenza a virus specific antibodies
BR112014013640A8 (pt) * 2011-12-05 2021-03-16 Trellis Bioscience Llc anticorpos úteis em imunização passiva para influenza
US20140335507A1 (en) * 2011-12-12 2014-11-13 Novartis Ag Assays for influenza virus hemagglutinins
KR101749316B1 (ko) 2011-12-15 2017-06-21 (주) 에이프로젠 Ｈ１ｎ１―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
RU2502745C2 (ru) * 2011-12-30 2013-12-27 Общество с ограниченной ответственностью "Технофарма" Наноантитело "anti-flu", рекомбинантные вирусные векторы и фармацевтические композиции для профилактики и терапии гриппа типа а
AU2013229488B2 (en) * 2012-03-08 2017-12-07 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
HK1207970A1 (en) 2012-05-10 2016-02-19 Massachusetts Institute Of Technology Agents for influenza neutralization
CN103665155B (zh) * 2012-09-14 2016-07-06 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1f2
CN103665157B (zh) * 2012-09-14 2016-06-29 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1c4
CN103665156B (zh) * 2012-09-14 2016-08-03 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的结合分子3e1
CN103665154B (zh) * 2012-09-14 2016-08-03 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子3c4
CN104968367B (zh) * 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
IL241552B2 (en) * 2013-03-14 2023-09-01 Contrafect Corp Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
EP2982691B1 (en) * 2013-04-02 2020-05-06 Xiamen University Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins
PL3052192T3 (pl) * 2013-10-02 2021-04-06 Medimmune, Llc Przeciwciała neutralizujące przeciwko grypie A i ich zastosowania
EP3070167A4 (en) * 2013-11-06 2017-06-07 Osaka University Antibody having broad neutralizing activity in group 1 influenza a virus
AU2015214146B2 (en) 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CN110642944B (zh) * 2014-03-07 2021-06-11 神州细胞工程有限公司 一种中和人感染h7n9甲型流感病毒的抗体及其用途
HRP20201530T1 (hr) 2014-05-13 2020-12-11 The Trustees Of The University Of Pennsylvania Kompozicije koje sadrže aav koji eksprimira konstrukte dvojnih antitijela i njihove primjene
JP6495434B2 (ja) * 2014-07-14 2019-04-03 ザ ペン ステイト リサーチ ファンデーション サーファクタントタンパク質ａ受容体を標的とする組成物及び方法
CN113563462B (zh) 2014-07-15 2024-08-13 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
JPWO2016010160A1 (ja) * 2014-07-18 2017-06-01 国立感染症研究所長 抗インフルエンザウイルス抗体及びその利用
US20180008702A1 (en) * 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
WO2016089181A1 (ko) * 2014-12-05 2016-06-09 (주)셀트리온 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US11535665B2 (en) 2015-05-13 2022-12-27 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
LT3303384T (lt) 2015-06-01 2021-10-11 Medimmune, Llc Neutralizuojančios surišančios molekulės prieš gripą ir jų naudojimas
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
US20170240617A1 (en) 2016-02-24 2017-08-24 Visterra, Inc. Formulations of antibody molecules to influenza virus
US12065482B2 (en) * 2016-08-10 2024-08-20 Celltrion Inc. Stable liquid pharmaceutical formulation of anti-influenza virus antibody
JP2017086068A (ja) * 2016-10-31 2017-05-25 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
RU2671477C2 (ru) * 2016-12-30 2018-10-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA2m1F16-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA2m1
RU2664184C2 (ru) * 2016-12-30 2018-08-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-Intht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IgA1
RU2656142C1 (ru) * 2016-12-30 2018-05-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA1
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
PT3589730T (pt) 2017-02-28 2024-02-28 Univ Pennsylvania Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
CN110573523A (zh) 2017-02-28 2019-12-13 宾夕法尼亚州大学信托人 基于aav载体的流感疫苗
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
US11685934B2 (en) 2017-09-18 2023-06-27 Amyris, Inc. Methods for genomic integration for Kluyveromyces host cells
BR112020005154A2 (pt) * 2017-09-18 2020-09-15 Amyris, Inc. métodos de integração genômica em pichia e outras células hospedeiras
CN109988236B (zh) * 2017-12-30 2022-04-01 中国科学院天津工业生物技术研究所 一种流感病毒抗体的应用
HRP20220980T1 (hr) * 2018-01-23 2022-11-11 Janssen Vaccines & Prevention B.V. Cjepiva protiv virusa influence i njihova uporaba
JP6622825B2 (ja) * 2018-01-25 2019-12-18 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
IL275884B2 (en) 2018-01-26 2024-11-01 Regeneron Pharma Human antibodies to influenza hemagglutinin
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
WO2020160560A2 (en) * 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
MY208974A (en) 2019-03-04 2025-06-14 Sumitomo Pharma Co Ltd Method for preparing influenza ha split vaccine
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2020048568A (ja) * 2019-11-22 2020-04-02 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
AU2020403133A1 (en) 2019-12-11 2022-06-23 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
CN111825763B (zh) * 2020-07-15 2022-04-19 扬州大学 流感病毒ha蛋白茎部特异性单克隆抗体及其制备方法和应用
CN114181303B (zh) * 2020-09-14 2022-12-23 东莞市朋志生物科技有限公司 抗甲型流感病毒的抗体和试剂盒
TW202237850A (zh) 2020-12-01 2022-10-01 賓州大學委員會 具有組織特異性靶向基序的新穎構成物及含有其之組成物
WO2022232289A1 (en) 2021-04-27 2022-11-03 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
KR20240088574A (ko) 2022-11-21 2024-06-20 (주)샤페론 인플루엔자 바이러스에 대한 단일 도메인 항체 및 이의 용도
CN119930806B (zh) * 2025-01-21 2025-12-02 中国医学科学院病原生物学研究所 一种甲型流感病毒中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630064A (en) * 1899-02-10 1899-08-01 William Martindale Safety-hook.
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
RU2031941C1 (ru) * 1991-03-14 1995-03-27 Научно-исследовательский институт гриппа РАМН Штамм вируса гриппа а(нini) для получения живой гриппозной интраназальной вакцины для взрослых и детей
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK1143006T3 (da) * 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US8101553B1 (en) * 2000-02-22 2012-01-24 Medical & Biological Laboratories Co., Ltd. Antibody library
AU2003251809A1 (en) 2002-07-11 2004-02-02 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
CN1756562A (zh) * 2003-03-07 2006-04-05 麦克公司 流感病毒疫苗
RU2390351C2 (ru) * 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
AU2007249160B2 (en) * 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
HRP20130163T1 (hr) * 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
EP2769992B1 (en) * 2006-10-02 2020-12-30 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008066691A2 (en) * 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
JP5346820B2 (ja) 2007-03-13 2013-11-20 エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US8871207B2 (en) * 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
AU2009275227A1 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof

Also Published As

Publication number Publication date
WO2010010466A2 (en) 2010-01-28
JP2011528902A (ja) 2011-12-01
AU2009275226A1 (en) 2010-01-28
CR20110079A (es) 2011-07-18
EP2313112A2 (en) 2011-04-27
GT201100023A (es) 2013-12-10
ZA201101113B (en) 2012-08-29
EP2313433A2 (en) 2011-04-27
JP2011528901A (ja) 2011-12-01
CN102164613B (zh) 2014-11-26
RU2553325C2 (ru) 2015-06-10
BRPI0911699B1 (pt) 2020-11-17
CA2733218A1 (en) 2010-01-28
MA32577B1 (fr) 2011-08-01
US20100080813A1 (en) 2010-04-01
KR20110047193A (ko) 2011-05-06
NZ590890A (en) 2013-05-31
CA2731686A1 (en) 2010-01-28
ES2662519T3 (es) 2018-04-06
IL210771A0 (en) 2011-03-31
US8685402B2 (en) 2014-04-01
WO2010010466A3 (en) 2010-07-29
CA2731686C (en) 2020-04-07
US9340603B2 (en) 2016-05-17
IL210772A0 (en) 2011-03-31
US20100086555A1 (en) 2010-04-08
CR20110084A (es) 2011-07-18
JP5607620B2 (ja) 2014-10-15
MX2011000768A (es) 2011-10-05
WO2010010467A3 (en) 2010-12-16
KR101732056B1 (ko) 2017-05-02
AU2009275227A1 (en) 2010-01-28
ECSP11010823A (es) 2011-08-31
EP2313112B1 (en) 2017-12-27
JP2014237714A (ja) 2014-12-18
BRPI0911699A2 (pt) 2014-09-23
CN102164613A (zh) 2011-08-24
CO6341572A2 (es) 2011-11-21
WO2010010467A2 (en) 2010-01-28
KR20110049802A (ko) 2011-05-12
MX2011000767A (es) 2011-09-21
ZA201101150B (en) 2012-08-29
HK1161110A1 (en) 2012-08-24
CN102216327A (zh) 2011-10-12
BRPI0911699B8 (pt) 2023-02-28
RU2011105062A (ru) 2012-08-27
JP6022515B2 (ja) 2016-11-09
AU2009275226B2 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
NZ590891A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
NZ594682A (en) Fully human antibodies specific to cadm1
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
NZ588238A (en) Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
NZ603498A (en) Human cytomegalovirus neutralizing antibodies and use thereof
NZ600022A (en) Anti CD37 antibodies
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
NZ597447A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ703653A (en) Anti-fap antibodies and methods of use
HRP20190643T1 (hr) Protutijela protiv dkk-1
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
NZ626269A (en) Anti-phf-tau antibodies and their uses
WO2008156763A3 (en) Human neutralizing monoclonal antibodies to h5n1 influenza a virus
NZ712765A (en) Antibodies that bind csf1r
NZ595235A (en) Compositions and methods for increasing muscle growth
NZ596295A (en) Anti-5T4 antibodies and uses thereof
PH12014501783B1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ585622A (en) Hepatitis c virus antibodies
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ616382A (en) Antibodies specific to cadherin-17
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF; FILING DATE: 04 FEB 2011; STATUS: REJECTED; TITLE: NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF; FILING DATE: 12 OCT 2012; STATUS: REJECTED; TITLE: NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF; FILING DATE: 19 APR 2011; STATUS: REJECTED; TITLE: NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF; FILING DATE: 30 AUG 2012; STATUS: REJECTED; TITLE: SPEC; FILING DATE: 16 NOV 2012; STATUS: PROPOSED;

Effective date: 20130306

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 JUL 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20130723

LAPS Patent lapsed